

Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

https://marketpublishers.com/r/H9C6722C3D98EN.html

Date: October 2019

Pages: 80

Price: US\$ 1,699.00 (Single User License)

ID: H9C6722C3D98EN

Abstracts

Hospital Acquired Pneumonia (HAP) Drug pipeline report- 2020 is an annual R&D review of Hospital Acquired Pneumonia (HAP) pipeline candidates. The report presents the current status of all major Hospital Acquired Pneumonia (HAP) therapeutic compounds. Detailed insights into Hospital Acquired Pneumonia (HAP) pipeline development, current status, companies, drug profiles and Hospital Acquired Pneumonia (HAP) preclinical and clinical trials are included.

2020 Hospital Acquired Pneumonia (HAP) Pipeline Market Insights
Hospital Acquired Pneumonia (HAP) disease overview, 2020 pipeline review, insights
into leading companies, dominant mechanism of action, majority of administration route
of Hospital Acquired Pneumonia (HAP) therapies, pipeline by phase and others are
included.

Hospital Acquired Pneumonia (HAP) pipeline Drug profiles-Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Hospital Acquired Pneumonia (HAP) Therapeutic Drug candidates Both active and inactive Hospital Acquired Pneumonia (HAP) pipeline drug candidates are included in the report

Hospital Acquired Pneumonia (HAP) Clinical Trials and preclinical Studies



Hospital Acquired Pneumonia (HAP) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Hospital Acquired Pneumonia (HAP) pipeline market developments
Hospital Acquired Pneumonia (HAP) Pipeline market news and deals including
mergers, acquisitions, approvals, collaborations, trial initiations, results, investments,
licensing opportunities and others are provided.

Hospital Acquired Pneumonia (HAP) pipeline companies in active development The report analyzes Hospital Acquired Pneumonia (HAP) pipeline of the below companies-

Aridis Pharmaceuticals Inc, AstraZeneca Plc, Biolytx Pharmaceuticals Corp, Centauri Therapeutics Ltd, Cumberland Pharmaceuticals Inc, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, EnBiotix Inc, Evaxion Biotech ApS, MedImmune LLC, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Motif Bio Plc, Nabriva Therapeutics plc, Peptineo, Polyphor AG, Sealife PHARMA GMBH, Shionogi & Co Ltd, Spero Therapeutics Inc, Tetraphase Pharmaceuticals Inc, TGV Laboratories Inc, Wockhardt Ltd

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

22 Companies investing in Hospital Acquired Pneumonia (HAP) pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Hospital Acquired Pneumonia (HAP) pipeline candidate are included

Company Profiles



Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included



Contents

1. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE MARKET INSIGHTS, 2020

- 1.1 Hospital Acquired Pneumonia (HAP) Disease Overview
- 1.2 Hospital Acquired Pneumonia (HAP) Drug Pipeline Snapshot, 2020
- 1.2.1 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Phase
- 1.2.2 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Company
- 1.2.3 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Mechanism of Action
- 1.2.4 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Route of Administration

2. HOSPITAL ACQUIRED PNEUMONIA (HAP) COMPANY WISE PIPELINE DETAILS

Aridis Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

AstraZeneca Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Biolytx Pharmaceuticals Corp Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Centauri Therapeutics Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Cumberland Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Destiny Pharma Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Dong-A Socio Holdings Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

EnBiotix Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Evaxion Biotech ApS Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile



Drug Candidate Details

MedImmune LLC Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Meiji Seika Pharma Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Merck & Co Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Motif Bio Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Nabriva Therapeutics plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Peptineo Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Polyphor AG Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Sealife PHARMA GMBH Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Shionogi & Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Spero Therapeutics Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Tetraphase Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

TGV Laboratories Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Wockhardt Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile



Drug Candidate Details

3. HOSPITAL ACQUIRED PNEUMONIA (HAP) DRUG PIPELINE PROFILES

- 3.1 Discovery and Preclinical Drug Profiles
- 3.2 Phase 1 Drug Profiles
- 3.3 Phase 2 Drug Profiles
- 3.4 Phase 3 Drug Profiles

4. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

- 5.1 Primary and Secondary Research Methodology
- 5.2 Publisher Expertize
- 5.3 Contacts



I would like to order

Product name: Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase,

Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and

Clinical Drugs

Product link: https://marketpublishers.com/r/H9C6722C3D98EN.html

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H9C6722C3D98EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970